Skip to content

Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto

Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto - Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000033832
Enrollment
15
Registered
2018-08-21
Start date
2018-08-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult

Interventions

Sponsors

Takanofoods Co., Ltd.
Lead Sponsor
Miura Clinic, Medical Corporation Kanonkai Oneness Support Co., Ltd.
Collaborator

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Postmenopausal women of ages 40 to 64 years old

Exclusion criteria

Exclusion criteria: 1. Persons who has liver disease, renal disease, digestive organ disease, heart trouble, peripheral vascular disorder, a person with a history of the past that may have an influence on other final examination results or person with a history of the operation 2. Person who take warfarin 3. Persons who liver function and renal function test values show abnormalities 4. Currently, those with a disorder under treatment 5. Persons who have food or drug allergy 6. Person who suffer from anemia 7. Persons who do intense sports or are on a diet 8. Persons who can't stop using functional foods (including Food for Specified Health Uses or Foods with Function Claims) and/or Specified quasi-drugs during the current study periods 9. Persons who are taking healthfoods, quasi medical items, medicines (including OTC, prescription medicine) containing ingredients contained in the test food 10. Persons who consume excess alcohol or can not abstinence from the day before the test until the day 11. Persons who are pregnant, or persons who are planning to become pregnant or breastfeeding during the study period 12. Persons who are participating in the other study or planning to participate during the study period 13. Persons who judged inappropriate by the study responsible doctor for other reasons

Design outcomes

Primary

MeasureTime frame
Blood (osteocalcin)

Secondary

MeasureTime frame
Urine (Type I collagen cross-linked N- telopeptide), Urine (deoxypyridinoline), Blood (vitamin K2)

Countries

Japan

Contacts

Public ContactMakoto Terashima

Oneness Support Co., Ltd. Clinical trial Division

mterashima@miura-cl.jp06-4801-8917

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026